search
Back to results

A Dose Determination Study of Chinese Herbal Medicine for Functional Constipation

Primary Purpose

Constipation

Status
Completed
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
MaZiRenWan (MZRW) Low dose
MaZiRenWan (MZRW) Median dose
MaZiRenWan (MZRW) High dose
Sponsored by
Hong Kong Baptist University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Constipation focused on measuring Randomized Controlled Trials, Medicine, Chinese Traditional, Medicine, Herbal, Constipation

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Clinical diagnosis of functional constipation with Rome II criteria General stool type belongs to Type 1 to 4 according to Bristol Stool Form Scale Complete spontaneous bowel movement≦2 movements per week Exclusion Criteria: Anti-diarrhoeal therapy Drug-induced constipation Medical history of important bowel pathology, such as inflammatory bowel disease, congenital or acquired megacolon / megarectum Medical history of previous abdominal surgery Taking chronic medications that contain any kind of herbs, mineral, or specific vitamin supplements Medical history of carbohydrate malabsorption, hormonal disorder, cancer, diabetes mellitus, hypothyroidism, asthma, renal impairment and/or any other serious diseases History of laxative abuse History of allergy to Chinese herbal medicine Psychiatric or addictive disorders Pregnancy or breast-feeding Any other serious diseases

Sites / Locations

  • Hong Kong Baptist University Chinese Medicine Clinic

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

MaZiRenWan (MZRW) Low dose

MaZiRenWan (MZRW) Median dose

MaZiRenWan (MZRW) High dose

Arm Description

MaZiRenWan (MZRW) Low dose 2.5g sachet by mouth, twice daily for 8 weeks

MaZiRenWan (MZRW) Median dose 5.0g sachet by mouth, twice daily for 8 weeks

MaZiRenWan (MZRW) High dose 7.5g sachet by mouth, twice daily for 8 weeks

Outcomes

Primary Outcome Measures

Responder for Complete Spontaneous Bowel Movement (CSBM)
Participants with a mean increase of CSBM>=1 movement per week compared with the last 14 days of the run-in period were defined as responders.CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.

Secondary Outcome Measures

Responder for Complete Spontaneous Bowel Movement (CSBM)
Participants with a mean increase of CSBM>=1 movement per week compared with the last 14 days of the run-in period were defined as responders. CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.
Bowel Movement
Complete Spontaneous Bowel Movement (CSBM)
CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.
Global Symptoms Improvement
Participants were asked to rate their impression of change in constipation by comparing with their baseline (Wk2) at the visits during the treatment (Wk6), end of treatment (Wk10) and end of follow-up (Wk18) with scores from 0 to 6 represented markedly worse or better respectively. The response categories were collapsed to simply "improved" for score 4 to 6, "same" for score 3 or "worse" for score 0 to 2.
Severity of Constipation
It was a 7-point ordinal scale from 0=not at all to 6=very severe.
Sensation of Straining
It was a 7-point ordinal scale from 0=not at all to 6=very severe.
Incomplete of Evacuation
It was a 7-point ordinal scale from 0=not at all to 6=very severe.
Sensation of Bloating
It was a 7-point ordinal scale from 0=not at all to 6=very severe.
Sensation of Abdominal Pain/Cramping
It was a 7-point ordinal scale from 0=not at all to 6=very severe.
Passing of Gas
It was a 7-point ordinal scale from 0=not at all to 6=very severe.
Adverse Effects (e.g. Renal and Liver Function Tests)
Blood Urea Level
Blood Creatinine Level
Serum Glutamic Pyruvic Transaminase(SGPT) Level
Serum Glutamic Oxaloacetic Transaminase(SGOT) Level

Full Information

First Posted
March 6, 2006
Last Updated
April 8, 2015
Sponsor
Hong Kong Baptist University
search

1. Study Identification

Unique Protocol Identification Number
NCT00299975
Brief Title
A Dose Determination Study of Chinese Herbal Medicine for Functional Constipation
Official Title
A Randomized Controlled Trial of Chinese Herbal Medicine in Three-dose Regimen for the Treatment of Functional Constipation
Study Type
Interventional

2. Study Status

Record Verification Date
April 2015
Overall Recruitment Status
Completed
Study Start Date
October 2006 (undefined)
Primary Completion Date
August 2007 (Actual)
Study Completion Date
October 2007 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hong Kong Baptist University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Functional constipation (FC) is common with 14.3% estimated prevalence in Hong Kong, but treatment for this condition in conventional medicine is suboptimal. Complementary and alternative medicines, especially Chinese herbal medicine (CHM) are used frequently by patients with FC, but there is little research evidence about these commonly used CHM. The purpose of the study is evaluate the efficacy and safety of CHM, as well as determining the optimal dosage.
Detailed Description
Functional constipation (FC) is a common complaint in clinical practice, with the estimated prevalence 14.3% in Hong Kong, as nearly affecting 1 million Hong Kong People in different extent. It is comparable with western population, which is 15% in North America. By the definition of Rome II criteria, FC comprises a group of functional disorders, which presents as persistent difficult, infrequent or seemingly incomplete defecation. Constipation is often perceived to be benign, easily treated condition with short-term treatment being relatively straightforward. However, the fact is the management of FC is perplexed as some subjects complain of constipation more than decade. Moreover, chronic constipation can develop into more serious bowel complaints, such as faecal impaction, incontinence and bowel perforations. There is also accumulating evidence shown that constipated subjects have significantly higher anxiety and depression scores and lower quality of life. Therefore, the demand of effective agents to normalize bowel function is extremely large. Conventional treatment for constipation mainly relies on dietary fibre and laxatives. Although there is no credible evidence that any serious problem is associated with their prolonged use, the treatment of it has been suboptimal. First, a recent systematic review pointed out that there were paucity of trials for many commonly used agents, therefore, their use might not be well validated. Second, many patients with severe constipation do not respond adequately or lose of effectiveness after a short period of time. Third, many patients who intake dietary fibre complain of flatulence, distension, bloating and poor taste. As a result, the compliance is low as about 50%. Fourth, the use of osmotic laxatives, such as polyethylene glycol, become increasingly popular due to fewer side effects and better taste, however, the prices are much more expensive than other medications. Many constipation sufferers seek help from alternative medicine, especially from Chinese herbal medicine. For example, according to a telephone survey in Hong Kong, more than 85% of constipated subjects seek for coping strategies, such as asking for medical consultations, taking prescribed medicine and seeking for alternative therapy, involving Chinese medicine. Traditional Chinese medicine (TCM) is particularly attractive as their effectiveness in treating functional disorders and retaining balance of body functions. The CHM used in study is derived from classic text of Chinese medicine (Shang Han Lun, Discussion of Cold-induced Disorders), which can "moisten the intestines, drain heat, promote the movement of qi and unblock the bowel". It is well known that randomized controlled trial (RCT) is the gold standard to test the efficacy of intervention, thus in this project, we attempt to follow the basic requirements of RCT to testify the efficacy and safety of CHM on FC, as well as to determine the optimal dosage. We believe such study will benefit the advancement of CHM, or even as the foundation of research study in future.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Constipation
Keywords
Randomized Controlled Trials, Medicine, Chinese Traditional, Medicine, Herbal, Constipation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
97 (Actual)

8. Arms, Groups, and Interventions

Arm Title
MaZiRenWan (MZRW) Low dose
Arm Type
Experimental
Arm Description
MaZiRenWan (MZRW) Low dose 2.5g sachet by mouth, twice daily for 8 weeks
Arm Title
MaZiRenWan (MZRW) Median dose
Arm Type
Experimental
Arm Description
MaZiRenWan (MZRW) Median dose 5.0g sachet by mouth, twice daily for 8 weeks
Arm Title
MaZiRenWan (MZRW) High dose
Arm Type
Experimental
Arm Description
MaZiRenWan (MZRW) High dose 7.5g sachet by mouth, twice daily for 8 weeks
Intervention Type
Drug
Intervention Name(s)
MaZiRenWan (MZRW) Low dose
Other Intervention Name(s)
Hemp Seed Pill
Intervention Description
Dissolved MaZiRenWan (MZRW) granule (2.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
Intervention Type
Drug
Intervention Name(s)
MaZiRenWan (MZRW) Median dose
Other Intervention Name(s)
Hemp Seed Pill
Intervention Description
Dissolved MaZiRenWan (MZRW) granule (5.0g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
Intervention Type
Drug
Intervention Name(s)
MaZiRenWan (MZRW) High dose
Other Intervention Name(s)
Hemp Seed Pill
Intervention Description
Dissolved MaZiRenWan (MZRW) granule (7.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
Primary Outcome Measure Information:
Title
Responder for Complete Spontaneous Bowel Movement (CSBM)
Description
Participants with a mean increase of CSBM>=1 movement per week compared with the last 14 days of the run-in period were defined as responders.CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.
Time Frame
Week3-10
Secondary Outcome Measure Information:
Title
Responder for Complete Spontaneous Bowel Movement (CSBM)
Description
Participants with a mean increase of CSBM>=1 movement per week compared with the last 14 days of the run-in period were defined as responders. CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.
Time Frame
Week11-18
Title
Bowel Movement
Time Frame
Baseline(Week1-2), Within treatment(Week3-10) & Within follow-up(Week11-18)
Title
Complete Spontaneous Bowel Movement (CSBM)
Description
CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.
Time Frame
Baseline(Week1-2), Within treatment(Week3-10) & Within follow-up(Week11-18)
Title
Global Symptoms Improvement
Description
Participants were asked to rate their impression of change in constipation by comparing with their baseline (Wk2) at the visits during the treatment (Wk6), end of treatment (Wk10) and end of follow-up (Wk18) with scores from 0 to 6 represented markedly worse or better respectively. The response categories were collapsed to simply "improved" for score 4 to 6, "same" for score 3 or "worse" for score 0 to 2.
Time Frame
Week6, 10 & 18
Title
Severity of Constipation
Description
It was a 7-point ordinal scale from 0=not at all to 6=very severe.
Time Frame
Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)
Title
Sensation of Straining
Description
It was a 7-point ordinal scale from 0=not at all to 6=very severe.
Time Frame
Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)
Title
Incomplete of Evacuation
Description
It was a 7-point ordinal scale from 0=not at all to 6=very severe.
Time Frame
Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)
Title
Sensation of Bloating
Description
It was a 7-point ordinal scale from 0=not at all to 6=very severe.
Time Frame
Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)
Title
Sensation of Abdominal Pain/Cramping
Description
It was a 7-point ordinal scale from 0=not at all to 6=very severe.
Time Frame
Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)
Title
Passing of Gas
Description
It was a 7-point ordinal scale from 0=not at all to 6=very severe.
Time Frame
Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)
Title
Adverse Effects (e.g. Renal and Liver Function Tests)
Time Frame
pre-treatment & post-treatment
Title
Blood Urea Level
Time Frame
Pre-treatment(Week2) & Post-treatment(Week10)
Title
Blood Creatinine Level
Time Frame
Pre-treatment(Week2) & Post-treatment(Week10)
Title
Serum Glutamic Pyruvic Transaminase(SGPT) Level
Time Frame
Pre-treatment(Week2) & Post-treatment(Week10)
Title
Serum Glutamic Oxaloacetic Transaminase(SGOT) Level
Time Frame
Pre-treatment(Week2) & Post-treatment(Week10)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of functional constipation with Rome II criteria General stool type belongs to Type 1 to 4 according to Bristol Stool Form Scale Complete spontaneous bowel movement≦2 movements per week Exclusion Criteria: Anti-diarrhoeal therapy Drug-induced constipation Medical history of important bowel pathology, such as inflammatory bowel disease, congenital or acquired megacolon / megarectum Medical history of previous abdominal surgery Taking chronic medications that contain any kind of herbs, mineral, or specific vitamin supplements Medical history of carbohydrate malabsorption, hormonal disorder, cancer, diabetes mellitus, hypothyroidism, asthma, renal impairment and/or any other serious diseases History of laxative abuse History of allergy to Chinese herbal medicine Psychiatric or addictive disorders Pregnancy or breast-feeding Any other serious diseases
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
ZhaoXiang Bian, PhD
Organizational Affiliation
Hong Kong Baptist University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hong Kong Baptist University Chinese Medicine Clinic
City
Hong Kong
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
21045817
Citation
Cheng CW, Bian ZX, Zhu LX, Wu JC, Sung JJ. Efficacy of a Chinese herbal proprietary medicine (Hemp Seed Pill) for functional constipation. Am J Gastroenterol. 2011 Jan;106(1):120-9. doi: 10.1038/ajg.2010.305. Epub 2010 Nov 2.
Results Reference
result
Links:
URL
http://www.ncbi.nlm.nih.gov/pubmed/21045817
Description
Abstract

Learn more about this trial

A Dose Determination Study of Chinese Herbal Medicine for Functional Constipation

We'll reach out to this number within 24 hrs